[1]贺 炜a,刘泓键b,易艳霞a,等.血清骨生成诱导因子及miR-22-3p 表达水平对2 型糖尿病肾病早期诊断价值研究[J].现代检验医学杂志,2023,38(02):37-42.[doi:10.3969/j.issn.1671-7414.2023.02.007 ]
　HE Weia,LIU Hong-jianb,YI Yan-xiaa,et al.Value of Serum Osteoinductive Factor and miR-22-3p Expression in the Early Diagnosis of Type 2 Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2023,38(02):37-42.[doi:10.3969/j.issn.1671-7414.2023.02.007 ]
点击复制

血清骨生成诱导因子及miR-22-3p 表达水平对2 型糖尿病肾病早期诊断价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年02期
页码:
37-42
栏目:
论著
出版日期:
2023-03-15

文章信息/Info

Title:
Value of Serum Osteoinductive Factor and miR-22-3p Expression in the Early Diagnosis of Type 2 Diabetic Nephropathy
文章编号:
1671-7414（2023）02-037-06
作者:
贺 炜a; 刘泓键b; 易艳霞a; 苏玉萍a; 占志鹏a
（重庆医科大学附属遂宁市中心医院 a.肾内科；b.泌尿外科，四川遂宁 629000）
Author(s):
HE Weia;  LIU Hong-jianb;  YI Yan-xiaa;  SU Yu-pinga;  ZHAN Zhi-penga
(a. Department of Nephrology; b. Department of Urology, Suining Central Hospital Affiliated to Chongqing Medical University, Sichuan Suining 629000,China)
关键词:
2型糖尿病肾病; 骨生成诱导因子; 微小核糖核酸 -22-3p
分类号:
R587.2；R392.11
DOI:
10.3969/j.issn.1671-7414.2023.02.007
文献标志码:
A
摘要:
目的 分析血清骨生成诱导因子（osteoinductive factor, OIF)和微小核糖核酸（microRNA, miR）-22-3p在 2型糖尿病肾病（type 2 diabetes nephropathy，T2DN）早期诊断中的价值。方法 选取 2018年 3月 ~2020年 3月重庆医科大学附属遂宁市中心医院 2型糖尿病患者 190例为研究对象，根据 24h尿微量清蛋白排泄率（24 hour urinary microalbumin excretion rate，24h UAER）分为糖尿病无肾病组（n=58）、早期糖尿病肾病组（n=62）及临床糖尿病肾病组（n=70）。并以同期体检的健康体检者 50例为健康对照组。比较各组血清 OIF和 miR-22-3p水平， Pearson法分析血清 OIF，miR-22-3p表达与肾功能指标的相关性。采用受试者工作曲线分析血清 OIF和 miR-22-3p及联合检测对早期 2型糖尿病肾病的诊断效能。结果 糖尿病无肾病组、早期糖尿病肾病组及临床糖尿病肾病组血清 OIF（7.81±1.31pg/ ml，9.75±1.45 pg/ml，13.44±1.61pg/ml）和 miR-22-3p（1.03±0.18，5.43±0.81，7.42±0.95）表达水平均高于健康对照组（6.42±1.22 pg/ml, 0.82±0.12），差异有统计学意义（t=5.675~48.790, 均 P<0.05）。早期糖尿病肾病组血清 OIF， miR-22-3p表达高于糖尿病无肾病组（t=7.673，40.436，均 P<0.05），临床糖尿病肾病组血清 OIF，miR-22-3p表达高于早期糖尿病肾病组（t=13.766，12.863，均 P<0.05），差异具有统计学意义。糖尿病无肾病组、早期糖尿病肾病组和临床糖尿病肾病组血清尿酸、糖化血红蛋白、24h UAER表达水平依次升高（t=1.847~47.555，均 P<0.05），eGFR表达水平依次降低（t=10.018，5.416，P<0.05），差异均有统计学意义。血清 OIF和 miR-22-3p表达水平与尿酸、糖化血红蛋白、 24h UAER呈正相关（r=0.510~0.604，均 P<0.01），与 eGFR呈负相关（r=-0.476，-0.408，均 P<0.01）；血清 OIF，miR-22-3p及联合检测对早期 2型糖尿病肾病诊断的曲线下面积（area under the curve，AUC）及 95%置信区间（95% confidence intervals，95%CI）分别为 0.815（95%CI：0.761～0.859），0.726（95%CI：0.706～0.812）及 0.893（95%CI：0.849～0.950）。联合检测血清 OIF，miR-22-3p对早期糖尿病肾病的诊断效能高于单一指标（Z=2.305，2.616，P=0.018，0.010）。结论 2型糖尿病肾病患者血清 OIF和 miR-22-3p表达升高，两者与尿酸、糖化血红蛋白、 24h UAER及 eGFR有关，联合检测有助于 2型糖尿病肾病的早期诊断。
Abstract:
Objective To analyze the value of serum osteoinductive factor (OIF) and microRNA (miR) - 22-3p in the early diagnosis of type 2 diabetes nephropathy（T2DN）. Methods 190 patients with type 2 diabetes diagnosed and treated in Suining Central Hospital Affiliated to Chongqing Medical University from March 2018 to March 2020 were selected as the study subjects,and according to 24 hour urinary microalbumin excretion rate(24h UAER),58 cases were divided into diabetes without nephropathy group, 62 cases into early diabetes nephropathy group and 70 cases into clinical diabetes nephropathy group,and 50 healthy control who had physical examination at the same time were selected as healthy control group.The levels of serum OIF and miR-22-3p in each group were compared. Pearson method was used to analyze the correlation between the expression of serum OIF, miR-22-3p and renal function related indicators.The diagnostic efficacy of serum OIF and miR-22-3p and their combined detection for early T2DN was analyzed by receiver operating curve. Results The expression levels of serum OIF (6.81 ± 1.31 pg/ml, 9.75 ± 1.45 pg/ml, 13.44 ± 1.61 pg / ml) and miR-22-3p (1.03 ± 0.18, 5.43 ± 0.81, 7.42 ± 0.95) in the diabetes without nephropathy group,early diabetic nephropathy group and clinical diabetes nephropathy group were higher than those in the healthy control group (6.42 ± 1.22 pg/ml, 0.82 ± 0.12), and the difference was statistically significant (t=5.675~48.790, all P < 0.05).The expression of serum OIF and miR-22-3p in early diabetes nephropathy group was higher than that in diabetes without nephropathy group (t=7.673, 40.436, all P<0.05), and the expression of serum OIF and miR-22-3p in clinical diabetes nephropathy group was higher than that in early diabetes nephropathy group (t=13.766, 12.863, all P<0.05), and the differences were statistically significant. The levels of serum uric acid, glycosylated hemoglobin and 24h UAER expression in diabetes non nephrotic group, early diabetes nephrotic group and clinical diabetes nephrotic group increased in turn (t=1.847~47.555, all P<0.05), and the level of eGFR expression decreased in turn (t=0.018, 5.416, P<0.05), and the differences were statistically significant, respectively. Serum OIF and miR-22-3p expression levels were positively correlated with uric acid, glycosylated hemoglobin and 24h UAER (r=0.510~0.604, all P<0.01), and negatively correlated with eGFR (r=-0.476, -0.408, all P<0.01).The area under the curve (AUC) and 95% confidence intervals(95% CI) of serum OIF, miR-22-3p and combined detection in the diagnosis of early diabetes nephropathy were 0.815 (95% CI:0.761~0.859), 0.726 (95% CI: 0.706~0.812) and 0.893 (95% CI:0.849~0.950), respectively. The diagnostic efficacy of combined detection of serum OIF and miR-22-3p for early diagnosis of T2DN was higher than that of single index (Z=2.305, 2.616, P=0.018, 0.010). Conclusion The expression of serum OIF and miR-22-3p in patients with T2DN was elevated, which were related to uric acid, glycosylated hemoglobin, 24h UAER and eGFR. Combined detection is helpful for the early diagnosis of T2DN.

参考文献/References:

[1] UMANATH K, LEWIS J B. Update on diabetic nephropathy: Core curriculum 2018[J].American Journal of Kidney Diseases, 2018,71(6):884-895.
[2] 沈伟兴 , 汤佳瑾 , 傅鹏 . 2型糖尿病肾病患者外周血 micorRNA-155水平与肾小球滤过率的相关性研究 [J]. 现代检验医学杂志 , 2022, 37(1):12-16,37.SHEN Weixing,TANG Jiajin,FU Peng. Correlation between microRNA-155 level in peripheral blood and glomerular filtration rate in patients with type 2 diabetic nephropathy [J]. Journal of Modern Laboratory Medicine,2022,37(1):12-16,37.
[3] 吴艳英 , 马郡 , 刘飞 ,等 . 糖尿病 560例肾脏病理类型分析 [J]. 武警医学 ,2021,32(7):625-627. WU Yanying, MA Jun, LIU Fei, et al.Analysis of renal pathological types in 560 cases of diabetes [J]. Medical Journal of the Chinese People’s Armed Police Force,2021,32 (7): 625-627.
[4] 龚伟 , 俞一飞 , 何敏 , 等 . 2型糖尿病合并慢性肾脏病且尿白蛋白正常者脉搏波传导速度变化及其危险因素分析 [J]. 中华糖尿病杂志 , 2020, 12(10) : 772-777. GONG Wei, YU Yifei, HE Min, et al. Change of pulse wave velocity and its risk factors in type 2 diabetes mellitus with normoalbuminuric chronic kidney disease [J]. Chinese Journal of Diabetes Mellitus,2020,12(10):772-777.
[5] ZHANG Yingying ,ZHAO Siqi ,WU Depei,et al. MicroRNA-22 promotes renal tubulointerstitial fibrosis by targeting PTEN and suppressing autophagy in diabetic nephropathy[J]. Journal of Diabetes Research, 2018,2018(Pt2):4728645.
[6] STARUP-LINDE J , VIGGERS R , HANDBERG A . Osteoglycin and bone-a systematic review[J]. Current Osteoporosis Reports, 2019, 17(27):250-255.
[7] WANG Zanxin，ZHUANG Xianian，CHEN Bailang, et al. Osteoglycin knockdown promotes vascular smooth muscle cell proliferation and migration in aortic dissection via the VEGF/VEGFR2 axis [J]. Molecular Medicine Repouts, 2021,23(1):65.
[8] WEI Wen,TU Mei,HUANG Rong,et al. Serum osteoinductive factor is associated with microalbuminuria and diabetic nephropathy in type 2 diabetes[J]. Medicine, 2018, 97(31):e11759.
[9] 中华医学会糖尿病学分会 .中国 2型糖尿病防治指南 (2017版 ) [J]. 中华糖尿病杂志 ,2018,10(1):4-67. Diabetes Society of Chinese Medical Association. Guidelines for the prevention and control of type 2 diabetes in China (2017 Edition) [J] . Chinese Journal of Diabetes Mellitus, 2018,10 (1): 4-67.
[10] HTAY T, SOE K, LOPEZ-PEREZ A, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes [J]. Curr Cardiol Rep, 2019,21(6):45.
[11] PALYGIN O , SPIRES D , LEVCHENKO V , et al. Progression of diabetic kidney disease in T2DN rats[J]. American Journal of Physiology. Renal Physiology, 2019, 317(6Pt2):F1450-F1461.
[12] 高倩 , 宋燕 , 王兵，等 . 血清 Hcy及尿 TRF，IgG， α1MG，NAG对 2型糖尿病肾病的早期诊断价值 [J]. 国际检验医学杂志 , 2021, 42(3):343-347. GAO Qian,SONG Yan,WANG Bing,et al. Early diagnostic value of serum Hey and urine TRF,Ig-G,α1MG,NAG in type 2 diabetic nephropathy [J]. International Journal of Laboratory Medi-cine,2021,42(3):343-347.
[13] 王杰 , 李冰 . 2型糖尿病肾病病理改变与肾脏预后的相关性研究 [J]. 中国中西医结合肾病杂志 , 2021, 22(1):85-87. WANG Jie, LI Bing.Study on the correlation between pathological changes of type 2 diabetes nephropathy and renal prognosis[J]. Chinese Journal of Integrated Traditional and Western Nephrology, 2021,22 (1): 85-87.
[14] 郭宜晨 , 鲁亚静 , 钟伟传 ,等 . 2型糖尿病患者外周血 miRNA表达谱差异研究 [J]. 现代检验医学杂志 ,2018,33(6):5-8. GUO Yichen,LU Yajing,ZHONG Weichuan, et al. Study on the difference of serum miRNA expression profile in peripheral blood of patients with type 2 diabetes mellitus [J].Journal of Modern Laboratory Medicine,2018,33(6):5-8.
[15] ISHII H , KANEKO S , YANAI K , et al. MicroRNAs in podocyte injury in diabetic nephropathy[J]. Frontiers in Genetics, 2020, 11:993.
[16] EPPLE C,HAUMER A, ISMAIL T, et al. Prefabrication of a large pedicled bone graft by engineering the germ for de novo vascularization and osteoinduction[J]. Biomaterials, 2018, 192:118-127.
[17] FASOLINO I, RAUCCI M G, SORIENTE A, et al. Osteoinductive and anti-inflammatory properties of chitosan-based scaffolds for bone regeneration [J]. Materials Science & Engineering. C, Materials for Biological Applications, 2019,105:110046.
[18] POfi R, fiORE D, DE GAETANO R, et al. Phospho-diesterase-5 inhibition preserves renal hemodynamics and function in mice with diabetic kidney disease by modulating miR-22 and BMP7[J]. Scientific Reports, 2017, 7:44584.
[19] GALINDO R J , BECK R W , SCIOSCIA M F , et al. Glycemic monitoring and management in advanced chronic kidney disease[J]. Endocrine Reviews, 2020， 41(5):756-774.

相似文献/References:

[1]沈伟兴a,汤佳瑾b,傅　鹏a.2型糖尿病肾病患者外周血 microRNA-155水平与肾小球滤过率的相关性研究[J].现代检验医学杂志,2022,37(01):12.[doi:10.3969/j.issn.1671-7414.2022.01.003]
　SHEN Wei-xinga,TANG Jia-jinb,FU Penga.Correlation between microRNA-155 Level in Peripheral Blood and Glomerular Filtration Rate in Patients with Type 2 DiabeticNephropathy[J].Journal of Modern Laboratory Medicine,2022,37(02):12.[doi:10.3969/j.issn.1671-7414.2022.01.003]

备注/Memo

备注/Memo:
收稿日期：2022-06-08修回日期：2022-11-02

更新日期/Last Update: 2023-03-15